Search Immortality Topics:


Challenge Awards-Class of 2017 | Prostate Cancer Foundation

Posted: September 23, 2018 at 7:45 am

Douglas McNeel, MD, PhD

2017 Movember Foundation Distinguished Gentlemans Ride PCF Challenge Award ($1 Million)

Principal Investigators: Douglas McNeel, MD, PhD (University of Wisconsin)

Co-Investigators: Glenn Liu, MD (University of Wisconsin), Robert Jeraj, PhD (University of Wisconsin), Christos Kyriakopoulos, MD (University of Wisconsin)

Project Title: Broadening T-Cell Activation with PD-1 Blockade to Treat Advanced, Metastatic Prostate Cancer

Description:

What this means to patients: Treatment strategies that effectively activate the immune system to target cancer will provide a promising new therapeutic opportunity for men with prostate cancer. Dr. McNeel and team will conduct a clinical trial testing the combination of two therapeutic prostate cancer vaccines plus the checkpoint immunotherapy anti-PD1, which may result in an effective new therapy for prostate cancer patients.

Felix Feng, MD

2017 Movember Foundation PCF Challenge Award ($1 Million)

Principal Investigators: Felix Feng, MD (University of California, San Francisco), Alan Ashworth, PhD (University of California, San Francisco), Charles Ryan, MD (University of California, San Francisco), Alexander Wyatt, PhD (University of British Columbia)

Co-Investigators: David Quigley, PhD (University of California, San Francisco), Li Zhang, PhD (University of California, San Francisco), Wassim Abida, MD, PhD (Memorial Sloan Kettering Cancer Center), Luke Gilbert, PhD (University of California, San Francisco)

Project Title: Identifying and Overcoming PARP Inhibitor Resistance in Patients with Metastatic Prostate Cancer

Description:

What this means to patients: PARP-inhibitors are a precision medicine that will likely gain FDA-approval for the treatment of advanced prostate cancer in the next few years. Dr. Feng and team will conduct studies that will optimize the use of these agents in patients, by identifying patients who are likely to benefit, uncovering mechanisms of PARP-inhibitor resistance, and discovering new treatments for patients who have progressed on PARP-inhibitors.

Joshua Lang, MD

2017 Movember Foundation PCF Challenge Award ($1 Million)

Principal Investigators: Joshua Lang, MD (University of Wisconsin), Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Scott Dehm, PhD (Masonic Cancer Center, University of Minnesota), Scott Tagawa, MD (Weill Cornell Medicine and New York-Presbyterian)

Co-Investigators: Kimberly Ku, MD (University of Wisconsin)

Project Title: Therapeutic Targeting of AR Variant Prostate Cancer with a Novel Antibody Drug Conjugate

Description:

What this means to patients: New treatments are critically needed for patients with advanced prostate cancer. Dr. Lang and team will conduct a clinical trial to test whether targeting TROP-2 with a drug-carrying antibody has promise for the treatment of prostate cancer patients and develop biomarkers that can be used to select patients who will benefit from this treatment.

Chad Mirkin, PhD

2017 Movember Foundation PCF Challenge Award ($1 Million)

Principal Investigators: Chad Mirkin, PhD (Northwestern University)

Co-Investigators: Bin Zhang, MD, PhD (Northwestern University), Timothy Kuzel, MD (Northwestern University), William Catalona, MD (Northwestern University), Andrew Lee, PhD (Northwestern University)

Project Title: Spherical Nucleic Acids as Therapeutic Vaccines for the Treatment of Prostate Cancer

Description:

What this means to patients: Therapies that effectively stimulate a persons immune system to attack and kill tumor cells are highly promising but still underdeveloped in prostate cancer. Dr. Mirkin and team will develop and test a novel nanoparticle-based therapeutic prostate cancer vaccine in preclinical models, which may lead to a new immunotherapy for prostate cancer.

Ana Aparicio, MD

2017 Movember Foundation PCF Challenge Award ($1 Million)

Principal Investigators: Ana Aparicio, MD (The University of Texas MD Anderson Cancer Center), Nicholas Navin, PhD (The University of Texas MD Anderson Cancer Center), Theocharis Panaretakis, PhD (The University of Texas MD Anderson Cancer Center), Peter Kuhn, PhD (University of Southern California)

Co-Investigators: Brian Chapin, MD (The University of Texas MD Anderson Cancer Center), James Hicks, PhD (University of Southern California), Patricia Troncoso, MD (The University of Texas MD Anderson Cancer Center)

Project Title: Impact of Local Therapy on Outcomes of Men with De Novo Metastatic Prostate Cancer within Molecularly Defined Subsets

Description:

What this means to patients: Some men who have metastatic prostate cancer at the time of diagnosis may benefit from treatment of the primary tumor in addition to standard systemic therapy. Dr. Aparicio and team will develop biomarkers that can be used to identify which of these patients will benefit from treatment of the primary prostate tumor. These data will be used to guide planned phase III clinical trials and may lead to a new standard of care for these patients.

Nupam Mahajan, PhD

2017 Movember Foundation PCF Challenge Award ($1 Million)

Principal Investigators: Nupam Mahajan, PhD (Washington University), Felix Feng, MD (University of California, San Francisco)

Co-Investigators: Jonathan Chou, MD (University of California, San Francisco), Kiran Mahajan, PhD (H. Lee Moffitt Cancer Center), Rajdeep Das, MBBS, PhD (University of California, San Francisco), Eric Small, MD (University of California, San Francisco), Amrita Basu, PhD (H. Lee Moffitt Cancer Center)

Project Title: Targeting Androgen Receptor and ACK1 Signaling with Novel Epigenetic Therapeutics in Castration-Resistant Prostate Cancer.

Description:

What this means to patients: New treatment strategies are needed for patients with hormone therapy-resistant prostate cancer. Dr. Mahajan and team will develop and optimize novel inhibitors of ACK1, a molecular pathway that regulates the androgen receptor, in preclinical studies. This may lead to a new prostate cancer treatment that is able to overcome resistance to AR-targeted therapies.

Howard Scher, MD

2017 PCF Challenge Award ($1 Million)

Award Donor: Janssen Pharmaceuticals

Principal Investigators: Howard Scher, MD (Memorial Sloan Kettering Cancer Center), Mary-Ellen Taplin, MD (Harvard: Dana-Farber Cancer Institute)

Co-Investigators: Wassim Abida, MD, PhD (Memorial Sloan Kettering Cancer Center), Anuradha Gopalan, MD (Memorial Sloan Kettering Cancer Center), Glenn Heller, PhD (Memorial Sloan Kettering Cancer Center), Maika Mitchell, PhD (Memorial Sloan Kettering Cancer Center), Nikolaus Schultz, PhD (Memorial Sloan Kettering Cancer Center), Steven Balk, MD, PhD (Harvard: Beth Israel Deaconess Medical Center), Atish Choudhury, MD, PhD (Harvard: Dana-Farber Cancer Institute), Eliezer Van Allen, MD (Harvard: Dana-Farber Cancer Institute), Adam Kibel, MD (Harvard: Brigham and Womens Hospital), Huihui Ye, MD, MSc (Harvard: Beth Israel Deaconess Medical Center), Rosina Lis, MD (Harvard: Dana-Farber Cancer Institute), Wai Yi Tsui, MD, PhD (Memorial Sloan Kettering Cancer Center), Michaela Bowden, PhD (Harvard: Dana-Farber Cancer Institute), Min Yuen Teo, MD (Memorial Sloan Kettering Cancer Center)

Project Title: Curing Lethal Non-Castrate Prostate Cancer: Integrative Molecular Analysis for Mechanisms of Exceptional Response, Resistance and Recurrence

Description:

What this means to patients: There is currently no curative treatment for men who are diagnosed with metastatic prostate cancer or those who relapse after treatment for primary prostate cancer. This team will test whether an intense, multimodal treatment strategy can be curative in these patients, and establish biomarkers for identifying the patients who should receive this treatment.

Scott Tagawa, MD

2017 PCF Challenge Award ($1 Million)

Award Donor: Stein Erik Hagen

Principal Investigators: Scott Tagawa, MD (Weill Cornell Medicine and NewYork-Presbyterian), Neil Bander, MD (Weill Cornell Medicine and NewYork-Presbyterian), Shankar Vallabhajosula, PhD (Weill Cornell Medicine and NewYork-Presbyterian)

Co-Investigators: John Babich, PhD (Weill Cornell Medicine and NewYork-Presbyterian), Karla Ballman, PhD (Weill Cornell Medicine and NewYork-Presbyterian), Himisha Beltran, MD (Weill Cornell Medicine and NewYork-Presbyterian), Yuliya Jhanwar, MD (Weill Cornell Medicine and NewYork-Presbyterian), Oliver Sartor, MD (Tulane University), Lauren Harshman, MD (Harvard: Dana-Farber Cancer Institute), Johannes Czernin, MD (University of California, Los Angeles), Sacha Gnjatic, MD (Icahn School of Medicine at Mount Sinai Hospital), Francesca Khani, MD (Weill Cornell Medicine and NewYork-Presbyterian)

Project Title: Optimization of Prostate-Specific Membrane Antigen-Targeted Radiation

Description:

What this means to patients: Recent studies have suggested that PSMA-targeted radiation therapy may be highly effective in men with advanced prostate cancer, however controlled clinical trials have not yet been conducted for these agents. This team will test several PSMA-targeted radiation therapies in clinical trials and optimize the use of these powerful new treatments for prostate cancer.

Shahneen Sandhu, MBBS

2017 PCF Challenge Award ($1 Million)

Award Donor: Stein Erik Hagen

Principal Investigators: Shahneen Sandhu, MBBS (University of Melbourne), Rodney Hicks, MD, MBBS (Peter MacCallum Cancer Centre), Michael Hofman, MBBS (Peter MacCallum Cancer Centre), Scott Williams, MD, MBBS (Peter MacCallum Cancer Centre), Carleen Cullinane, PhD, ScD (Peter MacCallum Cancer Centre), John Violet, MBBS, PhD (Peter MacCallum Cancer Centre), Paul Neeson, PhD, ScD (Peter MacCallum Cancer Centre)

Co-Investigators: David Goode, PhD, ScD (Peter MacCallum Cancer Centre), Lisa Horvath, MBBS, PhD (Chris OBrien Lifehouse), Anthony Joshua, MBBS, PhD (St Vincents Hospital, Kinghorn Cancer Centre), Carmel Pezaro, MBBS, (Monash University), Luc Furic, PhD, ScD (Peter MacCallum Cancer Centre)

Project Title: Harnessing Synergies between 177Lutate Therapy and Olaparib to Improve Clinical Outcome of Men with Metastatic Castration Resistant Prostate Cancer.

Description:

What this means to patients: Combining targeted radiation therapy with agents that prevent the repair of damaged DNA may be highly effective in the treatment of cancer. This team will conduct clinical trials to test the efficacy of combining a prostate cancer-targeting radiation therapy, 177Lu-PSMA, with the PARP-inhibitor olaparib, in advanced prostate cancer patients, and will identify mechanisms of action and biomarkers that can be used to select patients most likely to benefit from this treatment.

Johannes Czernin, MD

2017 PCF Challenge Award ($1 Million)

Award Donor: Stein Erik Hagen

Principal Investigators: Johannes Czernin, MD (University of California, Los Angeles), Caius Radu, MD (University of California, Los Angeles)

Co-Investigators: Robert Reiter, MD (University of California, Los Angeles), Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, PhD (University of California, Los Angeles)

Project Title: Elucidating mechanisms of effectiveness and resistance to Prostate Specific Membrane Antigen (PSMA) targeted Radioligand Therapy (RLT) using 177Lu-PSMA-617

Description:

What this means to patients: Cases reports have suggested that new PSMA-targeted radiation therapies such as 177Lu-PSMA-617 have much promise for the treatment of prostate cancer. This team will conduct a clinical trial testing 177Lu-PSMA-617 in advanced prostate cancer patients, and will identify possible mechanisms of treatment resistance and potential therapeutic targets for combination treatments that may improve patient outcomes.

Isla Garraway, MD, PhD

2017 PCF VALOR Challenge Award ($1 Million)

Award Donors: Richard Merkin, Todd Boehly

Principal Investigators: Isla Garraway, MD, PhD (University of California, Los Angeles), Beatrice Knudsen, MD, PhD (Cedars-Sinai Medical Center), Peter Kuhn, PhD (University of Southern California)

Co-Investigators:

Matthew Rettig, MD (University of California, Los Angeles), Nicholas Nickols, MD, PhD (University of California, Los Angeles), Stephen Freedland, MD (Cedars-Sinai Medical Center), James Hicks, PhD (Cold Spring Harbor Laboratory), Sungyong You, PhD (Cedars-Sinai Medical Center), Arkadiusz Gertych, PhD (Cedars-Sinai Medical Center), Michael Lewis, MD (Greater Los Angeles Veterans Affairs Healthcare System), Jeremy Shelton, MD (University of California, Los Angeles)

Project Title: Multiplatform Profiling of Lethal Prostate Cancer in the Veterans Affairs Population

Description:

What this means to patients: Increasing our understanding of the biology of metastatic prostate cancer will improve prostate cancer staging, prognosis and treatment. This team will profile mutations and genes expressed in prostate cancer samples from US Veterans throughout the course of clinical treatment to identify mechanisms and biomarkers of prostate cancer metastasis and treatment resistance.

Jeffrey Jones, MD, MSc

2017 PCF VALOR Challenge Award ($1 Million)

Award Donors: Peter Grauer, Robert Citrone

Principal Investigators: Jeffrey Jones, MD, MSc (Baylor College of Medicine and Michael E. DeBakey Veteran Affairs Medical Center), Michael Ittmann, MD (Baylor College of Medicine and Michael E. DeBakey Veteran Affairs Medical Center)

Co-Investigators: Rao Mandalapu, MD (Baylor College of Medicine), Arun Sreekumar, PhD (Baylor College of Medicine), Nancy Weigel, PhD (Baylor College of Medicine), Nora Navone, PhD (University of Texas MD Anderson Cancer Center), Curtis Pettaway, MD (University of Texas MD Anderson Cancer Center), Cheryl Walker, PhD (Baylor College of Medicine), Aihua Ed Yen, MD (Baylor College of Medicine), Nicholas Mitsiades, MD (Baylor College of Medicine), Cristian Coarfa, PhD (Baylor College of Medicine), Nagireddy Putluri, PhD (Baylor College of Medicine), Zhandong Liu, PhD (Baylor College of Medicine)

Project Title: Clinicopathological Correlation and Molecular Signature Identification and Risk Stratification of Prostate Cancer in African-American U.S. Veterans, With and Without Exposure to Battlefield Chemicals

Description:

What this means to patients: Factors such as race and chemical exposures can affect risk for prostate cancer and need to be better understood in order to improve prevention and treatment strategies. This team will study prostate cancer samples from US Veterans to better understand the biology of prostate cancer in African-American men and to elucidate the effects of exposure to battlefield chemicals such as Agent Orange on the development and progression of prostate cancer.

Amina Zoubeidi, PhD

2017 PCF Challenge Award ($1 Million)

Award Donors: Igor Tulchinsky, Milken Family Foundation

Principal Investigators: Amina Zoubeidi, PhD (Vancouver Prostate Centre; Vancouver Coastal Health Research Institute; University of British Columbia), Himisha Beltran, MD (Weill Cornell Medicine and NewYork-Presbyterian)

Co-Investigators: Robert Young, PhD (Simon Fraser University), Ravi Munuganti, PhD (University of British Columbia)

Project Title: Targeting BRN2 in Neuroendocrine Prostate Cancer

Description:

What this means to patients: Neuroendocrine prostate cancer (NEPC) is an aggressive and lethal subtype of prostate cancer that does not respond to hormonal therapy. This team will develop clinical trial-ready inhibitors of BRN2, a driver of NEPC, which may become a new treatment option for these patients.

Alicia Morgans, MD, MPH

Originally posted here:
Challenge Awards-Class of 2017 | Prostate Cancer Foundation

Recommendation and review posted by G. Smith